Got questions about the FDA’s decision on hydroxychloroquine? We’ve got you covered

On Monday the FDA revoked its controversial emergency use authorization for hydroxychloroquine, the unproven malaria drug touted as a cure for Covid-19. On paper, the decision will prevent the national stockpile from distributing the drug directly to hospitalized patients. But its impacts are likely much larger: Hydroxychloroquine mania led states to create their own stockpiles, inspired politicians to campaign on the issue, and pitted patients eager to try the drug against doctors skeptical of the evidence.

In a new story for STAT, I answer many of the unanswered questions surrounding the FDA’s decision. Check it out here.